{"id":"placebo-combined-with-letrozole","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Arthralgia/joint pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bone loss/osteoporosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Letrozole irreversibly inhibits the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. By reducing circulating estrogen levels, it suppresses the growth of hormone receptor-positive breast cancer cells. The placebo component suggests this is a controlled trial comparing letrozole efficacy against placebo control.","oneSentence":"Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:20.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer in postmenopausal women (likely adjuvant or extended therapy setting)"}]},"trialDetails":[{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04546009","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-09","conditions":"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","enrollment":992},{"nctId":"NCT05860465","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-08","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":254},{"nctId":"NCT07340658","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2026-05","conditions":"Advanced, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT02297438","phase":"PHASE3","title":"A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-03-23","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT05744687","phase":"PHASE2, PHASE3","title":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-04-24","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":374},{"nctId":"NCT02730429","phase":"PHASE2","title":"Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer","status":"COMPLETED","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2017-02-15","conditions":"Endometrial Cancer","enrollment":78},{"nctId":"NCT05257395","phase":"PHASE3","title":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-03-14","conditions":"Advanced Breast Cancer","enrollment":397},{"nctId":"NCT01958021","phase":"PHASE3","title":"Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-17","conditions":"Advanced, Metastatic Breast Cancer","enrollment":668},{"nctId":"NCT01740427","phase":"PHASE3","title":"A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02-22","conditions":"Breast Neoplasms","enrollment":666},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT05712941","phase":"PHASE3","title":"Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer","status":"WITHDRAWN","sponsor":"EQRx International, Inc.","startDate":"2023-04-18","conditions":"Endometrial Carcinoma","enrollment":""},{"nctId":"NCT05851014","phase":"PHASE3","title":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2022-01-14","conditions":"Breast Cancer","enrollment":350},{"nctId":"NCT05780567","phase":"PHASE3","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-30","conditions":"Breast Cancer","enrollment":1946},{"nctId":"NCT05439499","phase":"PHASE3","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2022-03-02","conditions":"Advanced Breast Cancer, Female Breast Cancer","enrollment":434},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT03966898","phase":"PHASE3","title":"A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-19","conditions":"Advanced Breast Cancer","enrollment":426},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT03081234","phase":"PHASE3","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-31","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00863655","phase":"PHASE3","title":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06-03","conditions":"Breast Cancer","enrollment":724},{"nctId":"NCT00422903","phase":"PHASE2","title":"Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Neoplasms, Breast","enrollment":92},{"nctId":"NCT00573755","phase":"PHASE2","title":"Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-12","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT02457312","phase":"PHASE2","title":"The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-03","conditions":"Pregnancy","enrollment":20},{"nctId":"NCT00499681","phase":"PHASE2","title":"PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2007-07","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT00083993","phase":"PHASE3","title":"Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-05","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":1236}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo combined with Letrozole","genericName":"Placebo combined with Letrozole","companyName":"Genor Biopharma Co., Ltd.","companyId":"genor-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design. Used for Hormone receptor-positive breast cancer in postmenopausal women (likely adjuvant or extended therapy setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}